Display options
Cite
Schroeder RJ, Audlin J, Luo J, et al. Pharmacokinetics of sodium thiosulfate in Guinea pig perilymph following middle ear application. J Otol. 2018;13(2):54-58doi: 10.1016/j.joto.2017.12.001.
Schroeder, R. J., Audlin, J., Luo, J., & Nicholas, B. D. (2018). Pharmacokinetics of sodium thiosulfate in Guinea pig perilymph following middle ear application. Journal of otology, 13(2), 54-58. https://doi.org/10.1016/j.joto.2017.12.001
Schroeder, Ronald J, et al. "Pharmacokinetics of sodium thiosulfate in Guinea pig perilymph following middle ear application." Journal of otology vol. 13,2 (2018): 54-58. doi: https://doi.org/10.1016/j.joto.2017.12.001
Schroeder RJ, Audlin J, Luo J, Nicholas BD. Pharmacokinetics of sodium thiosulfate in Guinea pig perilymph following middle ear application. J Otol. 2018 Jun;13(2):54-58. doi: 10.1016/j.joto.2017.12.001. Epub 2018 Feb 09. PMID: 30559765; PMCID: PMC6291635.
Copy Download .nbib Format: NLM
Share it on

J Otol. 2018 Jun;13(2):54-58. doi: 10.1016/j.joto.2017.12.001. Epub 2018 Feb 09.

Pharmacokinetics of sodium thiosulfate in Guinea pig perilymph following middle ear application.

Journal of otology

Ronald J Schroeder, Jason Audlin, Juntao Luo, Brian D Nicholas

Affiliations

  1. SUNY Upstate Medical University, USA.

PMID: 30559765 PMCID: PMC6291635 DOI: 10.1016/j.joto.2017.12.001

Abstract

HYPOTHESIS: To determine the pharmacokinetics of sodium thiosulfate in the inner ear perilymph following middle ear application in Guinea pigs.

BACKGROUND: Cisplatin chemotherapy is often associated with a dose-dependent high frequency sensorineural hearing loss. Sodium thiosulfate has been shown to reduce cisplatin-induced ototoxicity when given intravenously, but this may limit the tumoricidal effects of the chemotherapy. Recent animal studies looking at middle ear application of sodium thiosulfate have shown prevention of outer hair cell and hearing loss, but the perilymph pharmacokinetics have not yet been established.

METHODS: Twenty Guinea pig ears were split into two groups and administered sodium thiosulfate to the middle ear at either a concentration of 250 mg/mL or 50 mg/mL for 30 min. Perilymph samples were then obtained serially through the round window over 6 h. Sodium thiosulfate concentrations were obtained using high-pressure liquid chromatography.

RESULTS: The 250 mg/mL group had a maximum perilymph concentration of 7.27 mg/mL (±0.83) that decreased to 0.94 mg/mL (±0.03) over 6 h. The 50 mg/mL group had an initial concentration of 1.63 mg/mL (±0.17) and was undetectable after 1 h. The half-life of sodium thiosulfate within perilymph was 0.74 h.

CONCLUSIONS: and Relevance: The results of this study show that sodium thiosulfate is capable of diffusing through round window and into the inner ear perilymph. Peak levels decline over several hours after exposure. This has a potential application as a localized therapy in the prevention of cisplatin induced ototoxicity.

Keywords: Cisplatin; Ototoxicity; Perilymph; Pharmacokinetics; Sodium thiosulfate

References

  1. Laryngoscope. 1999 Jul;109(7 Pt 2):1-17 - PubMed
  2. Clin Cancer Res. 2000 Jan;6(1):309-15 - PubMed
  3. Otolaryngol Head Neck Surg. 2000 Apr;122(4):521-8 - PubMed
  4. Gastrointest Endosc. 2001 Feb;53(2):199-202 - PubMed
  5. Clin Cancer Res. 2001 Mar;7(3):493-500 - PubMed
  6. Acta Otorhinolaryngol Ital. 2002 Feb;22(1):14-8 - PubMed
  7. Br J Cancer. 2003 Apr 22;88(8):1199-206 - PubMed
  8. Neuropharmacology. 2003 Sep;45(3):380-93 - PubMed
  9. J Otolaryngol. 2003 Jun;32(3):146-50 - PubMed
  10. Hear Res. 2003 Aug;182(1-2):24-33 - PubMed
  11. Otol Neurotol. 2004 Jan;25(1):33-40 - PubMed
  12. Chem Pharm Bull (Tokyo). 1992 Nov;40(11):3000-4 - PubMed
  13. Otolaryngol Head Neck Surg. 2004 Jul;131(1):115-9 - PubMed
  14. Eur J Cancer. 2004 Nov;40(16):2445-51 - PubMed
  15. Neuroscience. 2005;135(1):263-71 - PubMed
  16. J Clin Oncol. 2005 Dec 1;23(34):8588-96 - PubMed
  17. ORL J Otorhinolaryngol Relat Spec. 2006;68(2):93-8 - PubMed
  18. Cancer. 2006 Jul 15;107(2):417-22 - PubMed
  19. Ann Emerg Med. 2007 Jun;49(6):806-13 - PubMed
  20. J Pediatr Hematol Oncol. 2007 Jun;29(6):355-60 - PubMed
  21. Clin J Am Soc Nephrol. 2007 Mar;2(2):258-63 - PubMed
  22. J Clin Oncol. 2007 Aug 20;25(24):3759-65 - PubMed
  23. Curr Opin Otolaryngol Head Neck Surg. 2007 Oct;15(5):364-9 - PubMed
  24. Clin Cancer Res. 2008 Jan 15;14(2):533-40 - PubMed
  25. Otol Neurotol. 2008 Apr;29(3):401-6 - PubMed
  26. Hear Res. 2008 May;239(1-2):79-91 - PubMed
  27. Nephrol Dial Transplant. 2008 Oct;23(10):3280-2 - PubMed
  28. J Assoc Res Otolaryngol. 2008 Sep;9(3):290-306 - PubMed
  29. Acta Otolaryngol. 2009 Feb;129(2):132-7 - PubMed
  30. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):779-88 - PubMed
  31. J Natl Cancer Inst. 2009 Jan 7;101(1):37-47 - PubMed
  32. J Otolaryngol Head Neck Surg. 2008 Oct;37(5):638-41 - PubMed
  33. Laryngoscope. 2010 Jul;120(7):1405-10 - PubMed
  34. Audiol Neurootol. 2011;16(4):233-41 - PubMed
  35. Cancer Chemother Pharmacol. 2011 Dec;68(6):1547-56 - PubMed
  36. Crit Rev Oncol Hematol. 1990;10(4):353-65 - PubMed
  37. Otol Neurotol. 2012 Jun;33(4):660-5 - PubMed
  38. Laryngoscope. 2013 Dec;123(12):3172-7 - PubMed
  39. Case Rep Nephrol Dial. 2015 Mar 13;5(1):77-82 - PubMed
  40. Actas Dermosifiliogr. 2016 May;107(4):359-62 - PubMed
  41. J Dermatolog Treat. 2016 Nov;27(6):520-524 - PubMed
  42. Lancet Oncol. 2017 Jan;18(1):63-74 - PubMed
  43. Biochem Pharmacol. 1987 Jun 15;36(12):1955-64 - PubMed
  44. Cancer. 1985 Oct 15;56(8):1934-9 - PubMed
  45. J Otolaryngol. 1983 Dec;12(6):365-9 - PubMed
  46. Cancer Chemother Pharmacol. 1995;36(1):83-6 - PubMed
  47. Eur Arch Otorhinolaryngol. 1997;254(6):281-6 - PubMed
  48. Otolaryngol Head Neck Surg. 1997 Nov;117(5):493-500 - PubMed
  49. Br J Cancer. 1998 Apr;77(8):1355-62 - PubMed
  50. J Pharmacol Exp Ther. 1998 Jul;286(1):77-84 - PubMed

Publication Types